A retrospective study assessing the impact of bone metastases and skeletal-related events on overall survival in patients with metastatic Non-small Cell Lung Cancer received first-line Pembrolizumab monotherapy or Pembrolizumab plus chemotherapy
Latest Information Update: 03 Mar 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer